Dupixent (dupilumab) is an antibody pharmaceutical. Dupilumab was first approved as Dupixent on 2017-03-28. It is used to treat atopic dermatitis in the USA. It has been approved in Europe to treat atopic dermatitis. The pharmaceutical is active against interleukin-4 receptor subunit alpha. In addition, it is known to target Interleukin-4 receptor subunit alpha.
|Drug Class||Monoclonal antibodies: fully human, immunomodulating|